Identification of protective Lassa virus epitopes that are restricted by HLA-A2

Journal of Virology

Volumn 80, Issue 17, 2006, Pages 8351-8361

  Botten, Jason ^a   Alexander, Jeff ^b   Pasquetto, Valerie ^c   Sidney, John ^c   Barrowman, Polly ^a   Ting, Joey ^a   Peters, Bjoern ^c   Southwood, Scott ^b   Stewart, Barbara ^b   Rodriguez Carreno, Maria P ^a   Mothe, Bianca ^c,d   Whitton, J Lindsay ^a   Sette, Alessandro ^c   Buchmeier, Michael J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Epimmune   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; NUCLEOPROTEIN; PEPTIDE; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN; VIRUS RNA;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSPOT ASSAY; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; LASSA FEVER; LASSA VIRUS; LEUKEMIA CELL LINE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STRAIN DIFFERENCE; TRANSGENIC MOUSE; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS GENOME; VIRUS INFECTION; VIRUS RECOMBINANT;

AMINO ACID SEQUENCE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; LASSA FEVER; LASSA VIRUS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NUCLEOCAPSID PROTEINS; PEPTIDES; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

LASSA VIRUS; MUS MUSCULUS; VACCINIA VIRUS;

EID: 33748655647     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00896-06     Document Type: Article

References (44)

1. Ahlers, J. D., I. M. Belyakov, S. Matsui, and J. A. Berzofsky. 2001. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol. 13:897-908.
2. Arichi, T., T. Saito, M. E. Major, I. M. Belyakov, M. Shirai, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky. 2000. Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model. Proc. Natl. Acad. Sci. USA 97:297-302.
3. Auperin, D. D., J. J. Esposito, J. V. Lange, S. P. Bauer, J. Knight, D. R. Sasso, and J. B. McCormick. 1988. Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res. 9:233-248.
4. Baldridge, J. R., T. S. McGraw, A. Paoletti, and M. J. Buchmeier. 1997. Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells. J. Virol. 71:755-758.
5. Blasco, R., and B. Moss. 1995. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158:157-162.
6. Boesen, A., K. Sundar, and R. Coico. 2005. Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T- lymphocyte responses in HLA-A2.1 transgenic mice. Clin. Diagn. Lab. Immunol. 12:1223-1230.
7. Bowen, M. D., P. E. Rollin, T. G. Ksiazek, H. L. Hustad, D. G. Bausch, A. H. Demby, M. D. Bajani, C. J. Peters, and S. T. Nichol. 2000. Genetic diversity among Lassa virus strains. J. Virol. 74:6992-7004.
8. Clegg, J. C., and G. Lloyd. 1987. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guinea pigs against Lassa fever. Lancet ii:186-188.
9. Clegg, J. C. S. 1992. Current progress towards vaccines for arenavirus-caused diseases. Vaccine 10:89-95.
10. Daftarian, P., S. Ali, R. Sharan, S. F. Lacey, C. La Rosa, J. Longmate, C. Buck, R. F. Siliciano, and D. J. Diamond. 2003. Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. J. Immunol. 171:4028-4039.
11. Doolan, D. L., S. L. Hoffman, S. Southwood, P. A. Wentworth, J. Sidney, R. W. Chesnut, E. Keogh, E. Appella, T. B. Nutman, A. A. Lai, D. M. Gordon, A. Oloo, and A. Sette. 1997. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 7:97-112.
12. Earl, P. L., B. Moss, L. S. Wyatt, and M. W. Carroll. 1998. Generation of recombinant vaccinia viruses, p. 16.17.1-16.17.19. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 2. John Wiley & Sons, Inc., New York, N.Y.
13. Fisher-Hoch, S. P., L. Hutwagner, B. Brown, and J. B. McCormick. 2000. Effective vaccine for lassa fever. J. Virol. 74:6777-6783.
14. Fisher-Hoch, S. P., and J. B. McCormick. 2001. Towards a human Lassa fever vaccine. Rev. Med. Virol. 11:331-341.
15. Fisher-Hoch, S. P., J. B. McCormick, D. Auperin, B. G. Brown, M. Castor, G. Perez, S. Ruo, A. Conaty, L. Brammer, and S. Bauer. 1989. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc. Natl. Acad. Sci. USA 86:317-321.
16. Geisbert, T. W., S. Jones, E. A. Fritz, A. C. Shurtleff, J. B. Geisbert, R. Liebscher, A. Grolla, U. Stroher, L. Fernando, K. M. Daddario, M. C. Guttieri, B. R. Mothe, T. Larsen, L. E. Hensley, P. B. Jahrling, and H. Feldmann. 2005. Development of a new vaccine for the prevention of Lassa fever. PLOS Med. 2:e183.
17. Gulukota, K., J. Sidney, A. Sette, and C. DeLisi. 1997. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J. Mol. Biol. 267:1258-1267.
18. Lukashevich, I. S., J. Patterson, R. Carrion, D. Moshkoff, A. Ticer, J. Zapata, K. Brasky, R. Geiger, G. B. Hubbard, J. Bryant, and M. S. Salvato. 2005. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J. Virol. 79:13934-13942.
19. McCormick, J. B. 1986. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med. Microbiol. Immunol. 175:153-155.
20. McCormick, J. B., and S. P. Fisher-Hoch. 2002. Lassa fever. Curr. Top. Microbiol. Immunol. 262:75-109.
21. McCormick, J. B., I. J. King, P. A. Webb, C. L. Scribner, R. B. Craven, K. M. Johnson, L. H. Elliott, and R. Belmont-Williams. 1986. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314:20-26.
22. Morrison, H. G., S. P. Bauer, J. V. Lange, J. J. Esposito, J. B. McCormick, and D. D. Auperin. 1989. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Virology 171:179-188.
23. Nielsen, M., C. Lundegaard, O. Lund, and C. Kesmir. 2005. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57:33-41.
24. Oldstone, M. B. A., H. Lewicki, D. Homann, C. Nguyen, S. Julien, and J. E. Gairin. 2001. Common antiviral cytotoxic T-lymphocyte epitope for diverse arenaviruses. J. Virol. 75:6273-6278.
25. Peters, C. J., P. B. Jahrling, C. T. Liu, R. H. Kenyon, K. T. McKee, Jr., and J. G. Barrera Oro. 1987. Experimental studies of arenaviral hemorrhagic fevers. Curr. Top. Microbiol. Immunol. 134:5-68.
26. Plebanski, M., K. L. Flanagan, E. A. Lee, W. H. Reece, K. Hart, C. Gelder, G. Gillespie, M. Pinder, and A. V. Hill. 1999. Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum. Immunity 10:651-660.
27. Price, M. E., S. P. Fisher-Hoch, R. B. Craven, and J. B. McCormick. 1988. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ 297:584-587.
28. Rodriguez-Carreno, M. P., M. S. Nelson, J. Botten, K. Smith-Nixon, M. J. Buchmeier, and J. L. Whitton. 2005. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 335:87-98.
29. Ruo, S. L., S. W. Mitchell, M. P. Kiley, L. F. Roumillat, S. P. Fisher-Hoch, and J. B. McCormick. 1991. Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies. J. Gen. Virol. 72:549-555.
30. Sette, A., and J. Fikes. 2003. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol. 15:461-470.
31. Sette, A., B. Livingston, D. McKinney, E. Appella, J. Fikes, J. Sidney, M. Newman, and R. Chesnut. 2001. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 29:271-276.
32. Sette, A., and J. Sidney. 1999. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50:201-212.
33. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. M. Melief, C. Oseroff, L. Yuan, J. Ruppert, J. Sidney, M. del Guercio, S. Southwood, R. T. Kubo, R. W. Chesnut, H. M. Grey, and F. V. Chisari. 1994. The relationship between class I binking affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586-5592.
34. Sidney, J., S. Southwood, C. Oseroff, M. F. Del Guercio, A. Sette, and H. Grey. 1998. Measurement of MHC/peptide interactions by gel filtration. Curr. Protocols Immunol. 18:18.3.1-18.3.19.
35. + T-cell peptide epitope of vaccinia and variola viruses. J. Virol. 78:7052-7060.
36. Southern, P. J. 1996. Arenaviridae: the viruses and their replication, p. 1505-1519. In B. N. Fields, D. M. Knipe, and P. M. Howley, et al (ed.), Fields Virology. Lippincott-Raven, Philadelphia, Pa.
37. Tangri, S., G. Y. Ishioka, X. Huang, J. Sidney, S. Southwood, J. Fikes, and A. Sette. 2001. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J. Exp. Med. 194:833-846.
38. Tenzer, S., B. Peters, S. Bulik, O. Schoor, C. Lemmel, M. M. Schatz, P. M. Kloetzel, H. G. Rammensee, H. Schild, and H. G. Holzhutter. 2005. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell. Mol. Life Sci. 62:1025-1037.
39. + T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J. Virol. 74:2186-2192.
40. ter Meulen, J., M. Badusche, J. Satoguina, T. Strecker, O. Lenz, C. Loeliger, M. Sakho, K. Koulemou, L. Koivogui, and A. Hoerauf. 2004. Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology 321:134-143.
41. U.S. Department of Health and Human Services. 1999. Biosafety in microbiological and biomedical laboratories, 4th ed. U.S. Government Printing Office, Washington, D.C.
42. van der Most, R. G., K. Murali-Krishna, J. L. Whitton, C. Oseroff, J. Alexander, S. Southwood, J. Sidney, R. W. Chesnut, A. Sette, and R. Ahmed. 1998. Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology 240:158-167.
43. Vitiello, A., D. Marchesini, J. Furze, L. A. Sherman, and R. W. Chesnut. 1991. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1007-1015.
44. Zhu, F., M. Yang, and D. D. Eckels. 2005. Interactions between helper T-cell epitopes of hepatitis C virus. Vaccine 23:3572-3580.